Citi lowered the firm’s price target on Caribou Biosciences (CRBU) to $6 from $30 and keeps a Buy rating on the shares. The firm updated models in the Smid-cap biotech space following the Q3 reports. Citi adjusted its launch timelines for Caribou ‘s three cell therapies in development, saying its prior timelines were too aggressive.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio